Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 7/20 | 0.56 |
| ▸ | TTR | P02766 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.46 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.46 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.46 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.46 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.46 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25181872 | 0.90 | USP30 (0.53) | RBP4TTRUSP30SCDEPHX2 | |
| SCHEMBL71246 | 0.88 | EPHX2 (0.56) | RBP4TTRSCDEPHX2 | |
| SCHEMBL20064249 | 0.85 | RORC (0.47) | RBP4USP30RORCCACNB4CACNA1A | |
| SCHEMBL28612120 | 0.84 | GPR119 (0.47) | RBP4USP30RORCCACNB4CACNA1A | |
| SCHEMBL4170411 | 0.82 | RBP4 (0.65) | RBP4TTRSCDEPHX2 | |
| SCHEMBL3954269 | 0.82 | USP30 (0.47) | RBP4USP30RORCCACNB4CACNA1A | |
| SCHEMBL26612279 | 0.81 | RBP4 (0.53) | RBP4TTR | |
| SCHEMBL2272549 | 0.81 | CACNB4 (0.43) | RBP4TTRUSP30RORCCACNB4 | |
| SCHEMBL10804110 | 0.81 | RBP4 (0.60) | RBP4TTRSCDEPHX2 | |
| SCHEMBL2270997 | 0.81 | PDE4B (0.48) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116507613-A | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | 纽约哥伦比亚大学理事会 | 2023-07-28 | — | — | CN | disclosed |
| EP-4181909-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | The Trustees Of Columbia University In The City Of New York (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022020305-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-2032566-A4 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD (CA) | 2009-07-08 | — | — | EP | disclosed |
| US-20090170828-A1 | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170828-A1 | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-07-02 | — | — | US | disclosed |
| US-20090170828-A1 | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-07-02 | — | — | US | disclosed |
| EP-2032566-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007143823-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007143823-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170828-A1 | Azetidine Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase | SCD, SCD5, FASN | RBP4 663/4885TTR 1408/4885USP30 2506/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | RBP4 2/4885TTR 1/4885USP30 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.